Further development and expansion of our Rare Diseases portfolio
Further strengthens the growth of ourrare disease franchise, in line with our3-yearstrategy, building on top of the current solid organic growth of the division
BroadensRecordati's rare disease therapeutic focus and enhances the breadth of indications, confirming our commitment to deliver treatments that address serious unmet medical needs
Diversifies the rare disease portfolioand adds in-market assets with growing trajectory expected to generate over €150 million of revenue by 2023 and peak sales of around €250 million (1)
Qarziba®is an anti-GD2 monoclonal antibody indicated forhigh-risk neuroblastoma approved in EU and other countries with potential for expansion in US
Sylvant®is ananti-IL-6monoclonal antibody, the first and only ever approved treatment for iMCD in US and EU, marketed also in other countries
Fotivda®is an oral highly selective small molecule (TKI) approved for first-line treatment of advanced renal cell carcinoma
Caphosol® is medical device for oral mucositis due to chemo and radio therapy, a niche product sold globally
ComplementsRecordati's global footprint and expertise with new rare and niche oncology disease capabilities, which will provide a platform for future further expansion in these areas
Confirms thehistory ofvalue-accretiveM&A strategy carried out by Recordati in recent years, with the transaction expected to generate approximately €50 million EBITDA(2)in 2023 and going EBITDA(2)margin in line with average of
Rare Disease segment
2
(1) Including Qarziba launch in US and in other geographies
(2) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, and non-recurring items
EUSA Pharma
Transformative assets with global growth potential, offering platform for further expansion
Company highlights
Overview
EUSA Pharma (UK), founded in 2015, is a world-class specialty pharmaceutical company
High growthportfolio of 4 in-market rare and niche oncology products
Profitableand cash generating business
Global commercial presencethrough direct operations mainly in EU and in US and some RoW countries, complemented with strategic partnerships
200+ peoplewith strong patient centric culture and deep disease area expertise
Biological products(2) with complex manufacturing process
Regional Revenue breakdown 2021 LTM (1)
13%
20%
67%
EMEA
North America
RoW
Product portfolio overview
#1 product in the EU forhigh-risk Neuroblastoma
Approved for newly diagnosed and relapse/refractory patients in EU and other countries
EU market exclusivity(ODD) 2027 and patent expiry (method of use) in 2034
Only treatment approved for iMCD in US and EU, marketed also in other countries
Productwith global growth potential with US main current market
Patent expiry in 2027 in US (sequence of CDR + method of production) and EU (composition of matter), with also market exclusivity in EU until 2024 (ODD) and in US until 2026 (BPCIA)
Monotherapy TKI with differentiated efficacy and tolerability for select patients with RCC
Approved in EU and other countries
EU market exclusivityuntil 2027 and patent expiry (composition of matter) in 2027
Prescription class I medical device for oral mucositis due to chemo and radio therapy
Synergistic promotional fit with adult solid tumor commercial
Approved in US, EU and other markets
EU patent expiry(formulation) in 2033
3 (1) Last twelve months revenue of approximately €130 million referring to 12-month period ending in June 2021
(2) Applies to Qarziba and Sylvant
Financial snapshot
Key business
financials
Value & funding
Expected over €150 million of revenue by 2023 and annual peak sales of~€250 million
EBITDA(1)~€50 million in 2023 with long term margin in line with average of Rare Disease segment
Non-recurringcosts in 2022-2023 from on-going manufacturing technology transfer and acquisition and integration expenses of ~€35 million (subject to timing of close)
Enterprise Value of €750 million
Net Debt of~€26 million at 30 June 2021
Financing with existing liquidity and bridge financing underwritten by J.P. Morgan and Mediobanca
Leverage
Below 2.5x at closing (pro-forma) and expected to return below 2.0x by 2023
Dividend policy confirmed as~60% of reported net income
Timing
Transaction closing, subject to regulatory clearances, expected in the first half of 2022
4
(1) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, and non-recurring items
Company declarations, disclaimers and profile
DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY'S FINANCIAL REPORTS
The manager responsible for preparing the company's financial reports Luigi La Corte declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finance, that the accounting information contained in this presentation corresponds to the document results, books and accounting records.
Statements contained in this presentation, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements.
All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.
Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.
Recordati S.p.A. published this content on 03 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 December 2021 12:11:02 UTC.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
